View source for 3,4-Methylenedioxyamphetamine

{{Short description|Entactogen, stimulant, and psychedelic drug of the amphetamine family}}
{{cs1 config|name-list-style=vanc}}
{{Use dmy dates|date=July 2020}}
{{Infobox drug
| Verifiedfields = verified
| Watchedfields = verified
| verifiedrevid = 646873547
| drug_name = MDA
| image = MDA-2D-skeletal.svg
| image_class = skin-invert-image
| width = 250px
| image2 = MDA molecule ball.png
| image_class2 = bg-transparent
| width2 = 250px

<!-- Clinical data -->
| INN = Tenamfetamine
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = 
| routes_of_administration = [[By mouth]], [[sublingual]], [[insufflation]], [[intravenous]]
| class = [[Serotonin–norepinephrine–dopamine releasing agent]]; [[Serotonin]] [[5-HT2 receptor|5-HT<sub>2</sub> receptor]] [[agonist]]; [[Entactogen]]; [[Empathogen]]; [[Serotonergic psychedelic]]; [[Hallucinogen]]; [[Stimulant]]

<!-- Legal status -->
| legal_AU = S9
| legal_BR = F2
| legal_BR_comment = <ref>{{cite web|department=Brazilian Health Regulatory Agency |date=2023-07-24 |title=RDC Nº 804 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial |trans-title=Collegiate Board Resolution No. 804 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control|url=https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-804-de-24-de-julho-de-2023-498447451 |url-status=live |archive-url=https://web.archive.org/web/20230827163149/https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-804-de-24-de-julho-de-2023-498447451 |archive-date=2023-08-27 |access-date=2023-08-27 |publisher=[[Diário Oficial da União]] |language=pt-BR |publication-date=2023-07-25}}</ref>
| legal_CA = Schedule I
| legal_DE = Anlage I
| legal_UK = Class A
| legal_US = Schedule I
| legal_UN = Psychotropic Schedule I

<!-- Pharmacokinetic data -->
| bioavailability = 
| protein_bound = 
| metabolism = [[Liver|Hepatic]] ([[Cytochrome P450 oxidase|CYP]] extensively involved)
| elimination_half-life = 10.9{{nbsp}}hours<ref name="BaggottGarrisonCoyle2019" />
| duration_of_action = 5–8{{nbsp}}hours<ref name="Oeri2021" /><ref name="BaggottGarrisonCoyle2019" />
| excretion = [[Kidney|Renal]]

<!-- Identifiers -->
| CAS_number_Ref = {{cascite|correct|CAS}}
| CAS_number = 4764-17-4
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = XJZ28FJ27W
| CAS_supplemental = 
| ATC_prefix = None
| ATC_suffix = 
| PubChem = 1614
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01509
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 1555
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 6731
| ChEBI = 166520
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D12715
| synonyms = MDA; Tenamfetamine; Amphedoxamine; Sally; Sassafras; Sass-a-frass; Sass; Mellow Drug of America; Hug drug; Love; 3,4-Methylenedioxy-α-methylphenethylamine; 5-(2-Aminopropyl)-1,3-benzodioxole; EA-1298; NSC-9978; NSC-27106; SKF-5

<!-- Chemical data -->
| IUPAC_name = 1-(2''H''-1,3-Benzodioxol-5-yl)propan-2-amine
| C=10 | H=13 | N=1 | O=2
| SMILES = NC(C)CC1=CC2=C(C=C1)OCO2
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C10H13NO2/c1-7(11)4-8-2-3-9-10(5-8)13-6-12-9/h2-3,5,7H,4,6,11H2,1H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = NGBBVGZWCFBOGO-UHFFFAOYSA-N
}}

'''3,4-Methylenedioxyamphetamine''' ('''MDA''') is an [[entactogen]], [[psychostimulant|stimulant]], and [[psychedelic drug]] of the [[substituted amphetamine|amphetamine]] and [[substituted methylenedioxyphenethylamine|MDxx]] families that is encountered mainly as a [[recreational drug]].<ref name="Oeri2021">{{cite journal | vauthors = Oeri HE | title = Beyond ecstasy: Alternative entactogens to 3,4-methylenedioxymethamphetamine with potential applications in psychotherapy | journal = J Psychopharmacol | volume = 35 | issue = 5 | pages = 512–536 | date = May 2021 | pmid = 32909493 | pmc = 8155739 | doi = 10.1177/0269881120920420 | url = }}</ref><ref name="HarpreetKarabulutGauld2023" /><ref name="PiHKAL1991">{{cite book | author1 = [[Alexander T. Shulgin]] | author2 = [[Ann Shulgin]] | chapter = #100 MDA 3,4-METHYLENEDIOXYAMPHETAMINE | pages = 714–719 | chapter-url = https://www.erowid.org/library/books_online/pihkal/pihkal100.shtml | title = PiHKAL: A Chemical Love Story | date = 1991 | publisher = Transform Press | edition = 1st | location = Berkeley, CA | isbn = 978-0-9630096-0-9 | oclc = 25627628 | url = https://books.google.com/books?id=O8AdHBGybpcC }}</ref> It is usually taken [[oral administration|orally]].<ref name="Oeri2021" /><ref name="PiHKAL1991" />

In terms of its [[pharmacology]], MDA is a [[serotonin–norepinephrine–dopamine releasing agent]] (SNDRA) and a [[serotonin]] [[5-HT2 receptor|5-HT<sub>2</sub> receptor]] [[agonist]], including of the serotonin [[5-HT2A receptor|5-HT<sub>2A</sub> receptor]].<ref name="Oeri2021" /> It has a [[duration of action|duration]] of 5 to 8{{nbsp}}hours.<ref name="Oeri2021" /><ref name="BaggottGarrisonCoyle2019" />

MDA has a long history of psychotherapeutic and recreational use that predates that of [[MDMA]], dating back to at least the mid-1960s.<ref name="Oeri2021" /><ref name="Sáez-BrionesHernández2013" /><ref name="HarpreetKarabulutGauld2023">{{cite journal | vauthors = Kaur H, Karabulut S, Gauld JW, Fagot SA, Holloway KN, Shaw HE, Fantegrossi WE | title = Balancing Therapeutic Efficacy and Safety of MDMA and Novel MDXX Analogues as Novel Treatments for Autism Spectrum Disorder | journal = Psychedelic Medicine | volume = 1 | issue = 3 | pages = 166–185 | date = September 2023 | pmid = 40046567 | pmc = 11661495 | doi = 10.1089/psymed.2023.0023 }}</ref> It has been described as the first entactogen.<ref name="BaggottGarrisonCoyle2019" /> MDA has also been described as probably the most popular [[structural analog|analogue]] of MDMA.<ref name="Sáez-BrionesHernández2013">{{cite journal | vauthors = Sáez-Briones P, Hernández A | title = MDMA (3,4-Methylenedioxymethamphetamine) Analogues as Tools to Characterize MDMA-Like Effects: An Approach to Understand Entactogen Pharmacology | journal = Curr Neuropharmacol | volume = 11 | issue = 5 | pages = 521–534 | date = September 2013 | pmid = 24403876 | pmc = 3763760 | doi = 10.2174/1570159X11311050007 | url = }}</ref> In most countries, the drug is a [[controlled substance]] and its possession and sale are illegal.

{{TOC limit|3}}

==Use and effects==
MDA is bought, sold, and used as a [[recreational drug]] due to its enhancement of [[mood (psychology)|mood]] and [[empathy]].<ref name="MonteMarona-LewickaCozzi1993">{{cite journal | vauthors = Monte AP, Marona-Lewicka D, Cozzi NV, Nichols DE | title = Synthesis and pharmacological examination of benzofuran, indan, and tetralin analogues of 3,4-(methylenedioxy)amphetamine | journal = Journal of Medicinal Chemistry | volume = 36 | issue = 23 | pages = 3700–3706 | date = November 1993 | pmid = 8246240 | doi = 10.1021/jm00075a027 }}</ref> It produces [[MDMA]]-like effects, including [[entactogen]]ic and [[stimulant]] effects, as well as mild [[psychedelic drug|psychedelic]] effects.<ref name="BaggottGarrisonCoyle2019" /><ref name="BaggottSiegristGalloway2010" /><ref name="BaggottSiegristCoyle2010">{{cite journal | vauthors = Baggott MJ, Siegrist J, Coyle JR, Flower K, Galloway G, Mendelson J | title=Poster Session III (PIII 1-84): PIII-09 Pharmacodynamic Effects of 3,4-Methylenedioxyamphetamine (MDA) | journal=Clinical Pharmacology & Therapeutics | volume=87 | issue=Suppl 1 | date=2010 | issn=0009-9236 | doi=10.1038/clpt.2009.277 | pages=S68–S95 (S70) | quote = In a placebo-controlled, double-blind, within-subjects study, 12 individuals received a single 98 mg/70 kg bw dose of MDA. This is the molar equivalent of 105 mg/ 70 kg bw MDMA, a well-studied dose. [...] MDA increased cortisol by 16.39 ug/dL (95%CI: 13.03-19.74, P < 1e-3) and prolactin by 18.37 ng/mL (95%CI: 7.39-29.35, P < 1e-3). These hormonal changes are comparable to those seen after MDMA. Heart rate increased by 9.05 bpm (95%CI: 6.10-11.99, P < 1e-5) and blood pressure increased by 18.98 / 12.73 mm Hg (Systolic 95%CI: 16.47 - 21.49, P < 1e-7; Diastolic 95%CI: 10.82 - 14.63, P < 1e-4). [...] There were robust self-report VAS changes in both MDMA-like (e.g., “closeness to others”) and hallucinogen-like (e.g., “familiar things seem unfamiliar”, time distortions, closed-eye visuals) effects that were generally similar to those seen after MDMA. [...] MDA is a psychoactive sympathomimetic phenethylamine with effects similar to MDMA. Although differences may exist in the magnitude of physiological effects, the overall profiles appear remarkably similar.}}</ref>

The dose range of MDA given in [[Alexander Shulgin]]'s book ''[[PiHKAL]]'' (''Phenethylamines I Have Known and Loved'') and other sources is 80 to 160{{nbsp}}mg.<ref name="PiHKAL1991" /><ref name="Oeri2021" /> A wider recreational dose range for MDA of 20 to 200{{nbsp}}mg or more, with a typical dose estimate of 90{{nbsp}}mg, has also been reported.<ref name="LuethiLiechti2018">{{cite journal | vauthors = Luethi D, Liechti ME | title = Monoamine Transporter and Receptor Interaction Profiles in Vitro Predict Reported Human Doses of Novel Psychoactive Stimulants and Psychedelics | journal = Int J Neuropsychopharmacol | volume = 21 | issue = 10 | pages = 926–931 | date = October 2018 | pmid = 29850881 | pmc = 6165951 | doi = 10.1093/ijnp/pyy047 | quote = Supplementary Table S1. Dose estimates and data sources for stimulants. [...]}}</ref> The dose range of MDA is very similar to that of MDMA.<ref name="PiHKAL1991" /><ref name="Oeri2021" /><ref name="LuethiLiechti2018" /><ref name="BaggottGarrisonCoyle2019" />

The effects of MDA include [[euphoria]], [[empathy]], emotional amplification, [[mental relaxation|relaxation]], feeling at peace with the world, increased [[introspection]], [[self-awareness]], and [[acceptance]], authenticity, clarity of thought, a desire to communicate with others and relate personal issues, and emotional bonding with others.<ref name="Oeri2021" /><ref name="Nichols1986" /><ref name="Shulgin1978" /> These effects led to MDA being called the "love drug" or "hug drug".<ref name="Nichols1986" /><ref name="PiHKAL1991" /> MDA also produces mild [[psychedelic drug|psychedelic]] effects, including brightened colors, [[closed-eye visual]]s or complex [[mental imagery]], [[synaesthesia]], and rarely mild [[hallucination]]s.<ref name="Oeri2021" /><ref name="BaggottGarrisonCoyle2019">{{cite journal | vauthors = Baggott MJ, Garrison KJ, Coyle JR, Galloway GP, Barnes AJ, Huestis MA, Mendelson JE | title = Effects of the Psychedelic Amphetamine MDA (3,4-Methylenedioxyamphetamine) in Healthy Volunteers | journal = Journal of Psychoactive Drugs | volume = 51 | issue = 2 | pages = 108–117 | date = 2019-03-15 | pmid = 30967099 | doi = 10.1080/02791072.2019.1593560 | s2cid = 106410946 }}</ref> It does not produce profound [[Hallucination|sensory disruption]] or overt hallucinations.<ref name="Nichols1986">{{cite journal | vauthors = Nichols DE | title = Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens | journal = J Psychoactive Drugs | volume = 18 | issue = 4 | pages = 305–313 | date = 1986 | pmid = 2880944 | doi = 10.1080/02791072.1986.10472362 | url = }}</ref><ref name="Shulgin1978" /> In any case, the drug has still been found to produce [[mystical experience|mystical]] or [[spiritual experience]]s.<ref name="BaggottSiegristGalloway2010" /><ref name="BaggottGarrisonCoyle2019" />

MDA shares most of MDMA's qualitative and emotional effects, including entactogenic and stimulant effects.<ref name="Oeri2021" /><ref name="Shulgin1978" /><ref name="BaggottGarrisonCoyle2019" /> However, it has been said to be slightly less stimulating than MDMA.<ref name="Oeri2021" /><ref name="BaggottGarrisonCoyle2019" /> In addition, MDA's [[hallucinogen]]ic effects are much greater than those of MDMA, although still less than those of classical psychedelics like [[psilocybin]].<ref name="Oeri2021" /><ref name="Nichols1986" /><ref name="BaggottGarrisonCoyle2019" /> Another difference between the two drugs is that MDA appears to produce a more introverted and emotionally intense prosocial state, while MDMA encourages a more extroverted and gregarious prosocial state.<ref name="BaggottGarrisonCoyle2019" />

Besides its [[psychoactive drug|psychoactive]] effects, MDA produces [[sympathomimetic]] effects such as increased [[heart rate]] and [[blood pressure]], among other [[physiology|physiological]] effects.<ref name="Sáez-BrionesHernández2013" /><ref name="Shulgin1978" /><ref name="BaggottGarrisonCoyle2019" />

In terms of the individual [[enantiomer]]s of MDA, (''R'')-MDA produces psychedelic effects and some entactogenic effects, while (''S'')-MDA is non-hallucinogenic, produces similar entactogenic effects as the [[racemic mixture|racemate]], and has considerable stimulant effects.<ref name="Nichols1986" /><ref name="Shulgin1978">{{cite book | veditors = Iversen LL, Iversen SD, Snyder SH | vauthors = Shulgin AT | title=Stimulants | chapter=Psychotomimetic Drugs: Structure-Activity Relationships | publisher=Springer US | publication-place=Boston, MA | date=1978 | isbn=978-1-4757-0512-6 | doi=10.1007/978-1-4757-0510-2_6 | pages=243–333 | chapter-url=https://bitnest.netfirms.com/external/10.1007/978-1-4757-0510-2_6 | url=https://books.google.com/books?id=h0_uBwAAQBAJ&pg=PA261}}</ref><ref name="PiHKAL1991" /> High doses of [[enantiopure]] (''R'')-MDA, in the range of 120 to 200{{nbsp}}mg, are described as closely resembling the effects of [[LSD]], for instance doses of 200 to 400{{nbsp}}μg.<ref name="Shulgin1978" /><ref name="YensenDiLeoRhead1976">{{cite journal | vauthors = Yensen R, Di Leo FB, Rhead JC, Richards WA, Soskin RA, Turek B, Kurland AA | title = MDA-assisted psychotherapy with neurotic outpatients: a pilot study | journal = J Nerv Ment Dis | volume = 163 | issue = 4 | pages = 233–245 | date = October 1976 | pmid = 972325 | doi = 10.1097/00005053-197610000-00002 | url = }}</ref> Enantiopure (''R'')-MDA at high doses produces more robust psychedelic effects than typical doses of racemic MDA.<ref name="Shulgin1978" /><ref name="YensenDiLeoRhead1976" /><ref name="PiHKAL1991" />

The [[duration of action|duration]] of MDA is about 5 to 8{{nbsp}}hours and is about 2{{nbsp}}hours longer than that of MDMA (3–6{{nbsp}}hours).<ref name="Oeri2021" /><ref name="BaggottGarrisonCoyle2019" /> Shulgin originally gave a duration of MDA of 8 to 12{{nbsp}}hours in ''PiHKAL'', but he later revised this down to only 3 to 6{{nbsp}}hours.<ref name="PiHKAL1991" /> A modern clinical study gave a duration of 6 to 8{{nbsp}}hours.<ref name="BaggottGarrisonCoyle2019" />

==Side effects==
[[Side effect]]s of MDA include [[sympathomimetic]] effects like increased [[heart rate]] and [[blood pressure]] as well as increased [[cortisol]] and [[prolactin]] levels.<ref name="BaggottGarrisonCoyle2019" /><ref name="BaggottSiegristCoyle2010" />

==Overdose==
Symptoms of acute toxicity may include [[Psychomotor agitation|agitation]], sweating, [[hypertension|increased blood pressure]] and [[tachycardia|heart rate]], [[hyperthermia|dramatic increase in body temperature]], [[convulsion]]s, and death. Death is usually caused by [[cardiac toxicity|cardiac effects]] and subsequent [[brain hemorrhage|hemorrhaging in the brain]] ([[stroke]]).<ref name="Diaz">{{cite book | vauthors = Diaz J| title = How Drugs Influence Behavior | location = Englewood Cliffs | publisher = Prentice Hall | date = 1996 }}</ref>{{medical citation needed|date=January 2015}}

==Interactions==
{{See also|MDMA#Interactions|Psychedelic drug#Interactions|Trip killer#Serotonergic psychedelic antidotes|Trip killer#Antidotes of other hallucinogens|MDMA/citalopram}}

==Pharmacology==
===Pharmacodynamics===
{{See also|MDMA#Pharmacodynamics|Entactogen#Mechanism of action|Serotonin releasing agent#Effects and comparisons|Monoamine releasing agent#Mechanism of action}}

{| class="wikitable floatright" style="font-size:small;"
|+ {{Nowrap|Activities of MDA}}
|-
! [[Biological target|Target]] !! [[Affinity (pharmacology)|Affinity]] (K<sub>i</sub>, nM)
|-
| {{Abbrlink|SERT|Serotonin transporter}} || 5,600–>10,000 (K<sub>i</sub>)<br />478–4,900 ({{Abbrlink|IC<sub>50</sub>|half-maximal inhibitory concentration}})<br />160–162 ({{Abbrlink|EC<sub>50</sub>|Half-maximal effective concentration}}) (rat)
|-
| {{Abbrlink|NET|Norepinephrine transporter}} || 13,000 (K<sub>i</sub>)<br />150–420 ({{Abbr|IC<sub>50</sub>|half-maximal inhibitory concentration}})<br />47–108 ({{Abbr|EC<sub>50</sub>|Half-maximal effective concentration}}) (rat)
|-
| {{Abbrlink|DAT|Dopamine transporter}} || >26,000 (K<sub>i</sub>)<br />890–20,500 ({{Abbr|IC<sub>50</sub>|half-maximal inhibitory concentration}})<br />106–190 ({{Abbr|EC<sub>50</sub>|Half-maximal effective concentration}}) (rat)
|-
| [[5-HT1A receptor|5-HT<sub>1A</sub>]] || 3,762–>10,000
|-
| [[5-HT1B receptor|5-HT<sub>1B</sub>]] || >10,000
|-
| [[5-HT1D receptor|5-HT<sub>1D</sub>]] || >10,000
|-
| [[5-HT1E receptor|5-HT<sub>1E</sub>]] || >10,000
|-
| [[5-HT1F receptor|5-HT<sub>1F</sub>]] || {{Abbr|ND|No data}}
|-
| [[5-HT2A receptor|5-HT<sub>2A</sub>]] || 3,200–>10,000 (K<sub>i</sub>)<br />630–1,767 ({{Abbr|EC<sub>50</sub>|half-maximal effective concentration}})<br />57–99% ({{Abbrlink|E<sub>max</sub>|maximal efficacy}})
|-
| [[5-HT2B receptor|5-HT<sub>2B</sub>]] || 91–100 (K<sub>i</sub>)<br />190–850 ({{Abbr|EC<sub>50</sub>|half-maximal effective concentration}})<br />51–80% ({{Abbr|E<sub>max</sub>|maximal efficacy}})
|-
| [[5-HT2C receptor|5-HT<sub>2C</sub>]] || 3,000–6,418 (K<sub>i</sub>)<br />98–4,800 ({{Abbr|EC<sub>50</sub>|half-maximal effective concentration}})<br />79–118% ({{Abbr|E<sub>max</sub>|maximal efficacy}})
|-
| [[5-HT3 receptor|5-HT<sub>3</sub>]] || >10,000
|-
| [[5-HT4 receptor|5-HT<sub>4</sub>]] || {{Abbr|ND|No data}}
|-
| [[5-HT5A receptor|5-HT<sub>5A</sub>]] || >10,000
|-
| [[5-HT6 receptor|5-HT<sub>6</sub>]] || >10,000
|-
| [[5-HT7 receptor|5-HT<sub>7</sub>]] || 3,548
|-
| [[Alpha-1A adrenergic receptor|α<sub>1A</sub>]] || 8,700–>10,000
|-
| [[Alpha-1B adrenergic receptor|α<sub>1B</sub>]] || >10,000
|-
| [[Alpha-1D adrenergic receptor|α<sub>1D</sub>]] || {{Abbr|ND|No data}}
|-
| [[Alpha-2A adrenergic receptor|α<sub>2A</sub>]] || 1,100–2,600
|-
| [[Alpha-2B adrenergic receptor|α<sub>2B</sub>]] || 690
|-
| [[Alpha-2C adrenergic receptor|α<sub>2C</sub>]] || 229
|-
| [[Beta-1 adrenergic receptor|β<sub>1</sub>]], [[Beta-2 adrenergic receptor|β<sub>2</sub>]] || >10,000
|-
| [[D1 receptor|D<sub>1</sub>]]–[[D5 receptor|D<sub>5</sub>]] || >10,000–>20,000<!-- D1: >12,000; D2: >20,000; D3: >17,000; D4: >10,000; D5: >10,000 -->
|-
| [[H1 receptor|H<sub>1</sub>]]–[[H4 receptor|H<sub>4</sub>]] || >10,000–>13,000 <!-- H1: >13,000; H2, H3, H4: >10,000 -->
|-
| [[Muscarinic acetylcholine M1 receptor|M<sub>1</sub>]]–[[Muscarinic acetylcholine M5 receptor|M<sub>5</sub>]] || {{Abbr|ND|No data}}
|-
| [[Nicotinic acetylcholine receptor|nACh]] || {{Abbr|ND|No data}}
|-
| [[Trace amine-associated receptor 1|TAAR1]] || 220–250 (K<sub>i</sub>) (rat)<br />740  ({{Abbr|EC<sub>50</sub>|half-maximal effective concentration}}) (rat)<br />86% ({{Abbr|E<sub>max</sub>|maximal efficacy}}) (rat)<br />160–180 (K<sub>i</sub>) (mouse)<br />580 ({{Abbr|EC<sub>50</sub>|half-maximal effective concentration}}) (mouse)<br />102% ({{Abbr|E<sub>max</sub>|maximal efficacy}}) (rat)<br />3,600 ({{Abbr|EC<sub>50</sub>|half-maximal effective concentration}}) (human)<br />11% ({{Abbr|E<sub>max</sub>|maximal efficacy}}) (human)
|-
| [[I1 receptor|I<sub>1</sub>]] || >10,000
|-
| [[Sigma-1 receptor|σ<sub>1</sub>]], [[Sigma-2 receptor|σ<sub>2</sub>]] || {{Abbr|ND|No data}}
|- class="sortbottom"
| colspan="2" style="width: 1px; background-color:var(--background-color-notice-subtle,#eaecf0); color:inherit; text-align: center;" | '''Notes:''' The smaller the value, the more avidly the drug binds to the site. Proteins are human unless otherwise specified. '''Refs:'''<ref name="PDSPKiDatabase">{{cite web | title=PDSP Database | website=UNC | url=https://pdsp.unc.edu/databases/pdsp.php?receptorDD=&receptor=&speciesDD=&species=&sourcesDD=&source=&hotLigandDD=&hotLigand=&testLigandDD=&testFreeRadio=testFreeRadio&testLigand=MDA&referenceDD=&reference=&KiGreater=&KiLess=&kiAllRadio=all&doQuery=Submit+Query | language=zu | access-date=13 December 2024}}</ref><ref name="BindingDB">{{cite web | vauthors = Liu T | title=BindingDB BDBM50005247 (+/-)2-Benzo[1,3]dioxol-5-yl-1-methyl-ethylamine::(-)2-Benzo[1,3]dioxol-5-yl-1-methyl-ethylamine::(R)-(-)-2-Benzo[1,3]dioxol-5-yl-1-methyl-ethylamine::(S)-(+)-2-Benzo[1,3]dioxol-5-yl-1-methyl-ethylamine::2-Benzo[1,3]dioxol-5-yl-1-methyl-ethylamine::2-Benzo[1,3]dioxol-5-yl-1-methyl-ethylamine((R)-(-)-MDA)::3,4-methylenedioxyamphetamine::CHEMBL6731::MDA::MDA, (R,S)::MDA,R(-)::Tenamfetamine::methylenedioxyamphetamine | website=BindingDB | url=https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50005247 | access-date=13 December 2024}}</ref><ref name="Ray2010">{{cite journal | vauthors = Ray TS | title = Psychedelics and the human receptorome | journal = PLOS ONE | volume = 5 | issue = 2 |article-number=e9019 | date = February 2010 | pmid = 20126400 | pmc = 2814854 | doi = 10.1371/journal.pone.0009019 | doi-access = free | bibcode = 2010PLoSO...5.9019R | url = }}</ref><ref name="LuethiKolaczynskaWalter2019">{{cite journal | vauthors = Luethi D, Kolaczynska KE, Walter M, Suzuki M, Rice KC, Blough BE, Hoener MC, Baumann MH, Liechti ME | title = Metabolites of the ring-substituted stimulants MDMA, methylone and MDPV differentially affect human monoaminergic systems | journal = J Psychopharmacol | volume = 33 | issue = 7 | pages = 831–841 | date = July 2019 | pmid = 31038382 | pmc = 8269116 | doi = 10.1177/0269881119844185 | url = }}</ref><ref name="KolaczynskaDucretTrachsel2022" /><ref name="RickliKopfHoener2015">{{cite journal | vauthors = Rickli A, Kopf S, Hoener MC, Liechti ME | title = Pharmacological profile of novel psychoactive benzofurans | journal = Br J Pharmacol | volume = 172 | issue = 13 | pages = 3412–3425 | date = July 2015 | pmid = 25765500 | pmc = 4500375 | doi = 10.1111/bph.13128 | url = }}</ref><ref name="SetolaHufeisenGrande-Allen2003">{{cite journal | vauthors = Setola V, Hufeisen SJ, Grande-Allen KJ, Vesely I, Glennon RA, Blough B, Rothman RB, Roth BL | title = 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro | journal = Mol Pharmacol | volume = 63 | issue = 6 | pages = 1223–1229 | date = June 2003 | pmid = 12761331 | doi = 10.1124/mol.63.6.1223 | url = }}</ref><br /><ref name="Blough2008" /><ref name="BrandtWaltersPartilla2020">{{cite journal | vauthors = Brandt SD, Walters HM, Partilla JS, Blough BE, Kavanagh PV, Baumann MH | title = The psychoactive aminoalkylbenzofuran derivatives, 5-APB and 6-APB, mimic the effects of 3,4-methylenedioxyamphetamine (MDA) on monoamine transmission in male rats | journal = Psychopharmacology (Berl) | volume = 237 | issue = 12 | pages = 3703–3714 | date = December 2020 | pmid = 32875347 | pmc = 7686291 | doi = 10.1007/s00213-020-05648-z | url = }}</ref><ref name="GainetdinovHoenerBerry2018">{{cite journal | vauthors = Gainetdinov RR, Hoener MC, Berry MD | title = Trace Amines and Their Receptors | journal = Pharmacol Rev | volume = 70 | issue = 3 | pages = 549–620 | date = July 2018 | pmid = 29941461 | doi = 10.1124/pr.117.015305 | url = | doi-access = free }}</ref><ref name="SimmlerBuchyChaboz2016">{{cite journal | vauthors = Simmler LD, Buchy D, Chaboz S, Hoener MC, Liechti ME | title = In Vitro Characterization of Psychoactive Substances at Rat, Mouse, and Human Trace Amine-Associated Receptor 1 | journal = J Pharmacol Exp Ther | volume = 357 | issue = 1 | pages = 134–144 | date = April 2016 | pmid = 26791601 | doi = 10.1124/jpet.115.229765 | url = https://d1wqtxts1xzle7.cloudfront.net/74120533/eae6c6e62565b82d46b4d111bbea0f77b9c2-libre.pdf?1635931703=&response-content-disposition=inline%3B+filename%3DIn_Vitro_Characterization_of_Psychoactiv.pdf&Expires=1746838268&Signature=Sy4fJ90yUhxs68314NxYsW5PAaNrBGePRu35WRR4PIF-3YC7Z~sLdnCn5wfqqbLg9bDEGdt~oW55ugMP3D3jgA0BoRI~~GOb0NQOwrtfUEQK1PQs1uuN9qg5Y1ct8z5NsABm44RgtukkwRMdU6fO7OlfIsQ68hOiFk129Ll7UYqldxD2f1xhE2fTTfsxSpb8cMCJzHn7-ItqLdwnAUPFK7WggDIjmY1kCnaHLwIxMwdJCAq8L6DYzSTg7pZkbR8qlou~GXbTPQt~gYpyZTJp5hgW-7V6K5wLlQ7Z2xE7B0f9wEfuc1W1QNafg125Tr-vvAe4LEGKXV58bnn1bpfWKw__&Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA | archive-url = https://web.archive.org/web/20250509235235/https://d1wqtxts1xzle7.cloudfront.net/74120533/eae6c6e62565b82d46b4d111bbea0f77b9c2-libre.pdf?1635931703=&response-content-disposition=inline%3B+filename%3DIn_Vitro_Characterization_of_Psychoactiv.pdf&Expires=1746838268&Signature=Sy4fJ90yUhxs68314NxYsW5PAaNrBGePRu35WRR4PIF-3YC7Z~sLdnCn5wfqqbLg9bDEGdt~oW55ugMP3D3jgA0BoRI~~GOb0NQOwrtfUEQK1PQs1uuN9qg5Y1ct8z5NsABm44RgtukkwRMdU6fO7OlfIsQ68hOiFk129Ll7UYqldxD2f1xhE2fTTfsxSpb8cMCJzHn7-ItqLdwnAUPFK7WggDIjmY1kCnaHLwIxMwdJCAq8L6DYzSTg7pZkbR8qlou~GXbTPQt~gYpyZTJp5hgW-7V6K5wLlQ7Z2xE7B0f9wEfuc1W1QNafg125Tr-vvAe4LEGKXV58bnn1bpfWKw__&Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA | archive-date = 9 May 2025 }}</ref>
|}

MDA is a [[Substrate (biochemistry)|substrate]] of the [[serotonin transporter|serotonin]], [[norepinephrine transporter|norepinephrine]], [[dopamine transporter|dopamine]], and [[vesicular monoamine transporter]]s, and in relation to this, acts as a [[reuptake inhibitor]] and [[releasing agent]] of [[serotonin]], [[norepinephrine]], and [[dopamine]] (that is, it is an {{abbrlink|SNDRA|serotonin–norepinephrine–dopamine releasing agent}}).<ref name="Oeri2021" /><ref name="pmid17017961">{{cite journal | vauthors = Rothman RB, Baumann MH | title = Therapeutic potential of monoamine transporter substrates | journal = Current Topics in Medicinal Chemistry | volume = 6 | issue = 17 | pages = 1845–1859 | year = 2006 | pmid = 17017961 | doi = 10.2174/156802606778249766 | url = https://zenodo.org/record/1235860 }}</ref> It is also an [[agonist]] of the serotonin [[5-HT2A receptor|5-HT<sub>2A</sub>]],<ref name="GiovanniMatteo2008">{{cite book| vauthors = Di Giovanni G, Di Matteo V, Esposito E |title=Serotonin–dopamine Interaction: Experimental Evidence and Therapeutic Relevance|url=https://books.google.com/books?id=mPkKtA15KM8C&pg=PA294|year=2008|publisher=Elsevier|isbn=978-0-444-53235-0|pages=294–}}</ref> [[5-HT2B receptor|5-HT<sub>2B</sub>]],<ref name="RothmanBaumann2009">{{cite journal | vauthors = Rothman RB, Baumann MH | title = Serotonergic drugs and valvular heart disease | journal = Expert Opinion on Drug Safety | volume = 8 | issue = 3 | pages = 317–329 | date = May 2009 | pmid = 19505264 | pmc = 2695569 | doi = 10.1517/14740330902931524 }}</ref> and [[5-HT2C receptor|5-HT<sub>2C</sub> receptors]]<ref name="pmid7824160">{{cite journal | vauthors = Nash JF, Roth BL, Brodkin JD, Nichols DE, Gudelsky GA | title = Effect of the R(−) and S(+) isomers of MDA and MDMA on phosphatidyl inositol turnover in cultured cells expressing 5-HT2A or 5-HT2C receptors | journal = Neuroscience Letters | volume = 177 | issue = 1–2 | pages = 111–115 | date = August 1994 | pmid = 7824160 | doi = 10.1016/0304-3940(94)90057-4 | author2-link = Bryan Roth | s2cid = 41352480 }}</ref> and shows [[affinity (pharmacology)|affinity]] for the [[Alpha-2A adrenergic receptor|α<sub>2A</sub>-]], [[Alpha-2B adrenergic receptor|α<sub>2B</sub>-]], and [[Alpha-2C adrenergic receptor|α<sub>2C</sub>-adrenergic receptors]] and serotonin [[5-HT1A receptor|5-HT<sub>1A</sub>]] and [[5-HT7 receptor|5-HT<sub>7</sub> receptors]].<ref name="ManzoniRay2010">{{cite journal | vauthors = Ray TS | title = Psychedelics and the human receptorome | journal = PLOS ONE | volume = 5 | issue = 2 |article-number=e9019 | date = February 2010 | pmid = 20126400 | pmc = 2814854 | doi = 10.1371/journal.pone.0009019 | doi-access = free | bibcode = 2010PLoSO...5.9019R }}</ref>

In addition to its actions as a monoamine releasing agent, MDA is a potent high-[[efficacy]] [[partial agonist]] or [[full agonist]] of the rodent TAAR1.<ref name="GainetdinovHoenerBerry2018" /><ref name="SimmlerBuchyChaboz2016" /> Conversely, MDA is much weaker in terms of [[potency (pharmacology)|potency]] as an agonist of the human TAAR1.<ref name="GainetdinovHoenerBerry2018" /><ref name="SimmlerBuchyChaboz2016" /><ref name="LewinMillerGilmour2011">{{cite journal | vauthors = Lewin AH, Miller GM, Gilmour B | title = Trace amine-associated receptor 1 is a stereoselective binding site for compounds in the amphetamine class | journal = Bioorganic & Medicinal Chemistry | volume = 19 | issue = 23 | pages = 7044–7048 | date = December 2011 | pmid = 22037049 | pmc = 3236098 | doi = 10.1016/j.bmc.2011.10.007 }}</ref> Moreover, MDA acts as a very weak partial agonist or [[receptor antagonist|antagonist]] of the human TAAR1 rather than as an efficacious agonist.<ref name="GainetdinovHoenerBerry2018" /><ref name="SimmlerBuchyChaboz2016" /> TAAR1 activation is thought to auto-inhibit and constrain the effects of amphetamines that act as TAAR1 agonists, for instance MDMA in rodents.<ref name="EspinozaGainetdinov2014">{{cite book | vauthors = Espinoza S, Gainetdinov RR | title=Taste and Smell | chapter=Neuronal Functions and Emerging Pharmacology of TAAR1 | series=Topics in Medicinal Chemistry | publisher=Springer International Publishing | publication-place=Cham | volume=23 | date=2014 | isbn=978-3-319-48925-4 | doi=10.1007/7355_2014_78 | pages=175–194 | quote = Interestingly, the concentrations of amphetamine found to be necessary to activate TAAR1 are in line with what was found in drug abusers [3, 51, 52]. Thus, it is likely that some of the effects produced by amphetamines could be mediated by TAAR1. Indeed, in a study in mice, MDMA effects were found to be mediated in part by TAAR1, in a sense that MDMA auto-inhibits its neurochemical and functional actions [46]. Based on this and other studies (see other section), it has been suggested that TAAR1 could play a role in reward mechanisms and that amphetamine activity on TAAR1 counteracts their known behavioral and neurochemical effects mediated via dopamine neurotransmission. }}</ref><ref name="KuropkaZawadzkiSzpot2023">{{cite journal | vauthors = Kuropka P, Zawadzki M, Szpot P | title = A narrative review of the neuropharmacology of synthetic cathinones-Popular alternatives to classical drugs of abuse | journal = Hum Psychopharmacol | volume = 38 | issue = 3 | article-number = e2866 | date = May 2023 | pmid = 36866677 | doi = 10.1002/hup.2866 | url = | quote = Another feature that distinguishes [synthetic cathinones (SCs)] from amphetamines is their negligible interaction with the trace amine associated receptor 1 (TAAR1). Activation of this receptor reduces the activity of dopaminergic neurones, thereby reducing psychostimulatory effects and addictive potential (Miller, 2011; Simmler et al., 2016). Amphetamines are potent agonists of this receptor, making them likely to self‐inhibit their stimulating effects. In contrast, SCs show negligible activity towards TAAR1 (Kolaczynska et al., 2021; Rickli et al., 2015; Simmler et al., 2014, 2016). [...] It is worth noting, however, that for TAAR1 there is considerable species variability in its interaction with ligands, and it is possible that the in vitro activity of [rodent TAAR1 agonists] may not translate into activity in the human body (Simmler et al., 2016). The lack of self‐regulation by TAAR1 may partly explain the higher addictive potential of SCs compared to amphetamines (Miller, 2011; Simmler et al., 2013). }}</ref><ref name="SimmlerBuserDonzelli2013">{{cite journal | vauthors = Simmler LD, Buser TA, Donzelli M, Schramm Y, Dieu LH, Huwyler J, Chaboz S, Hoener MC, Liechti ME | title = Pharmacological characterization of designer cathinones in vitro | journal = Br J Pharmacol | volume = 168 | issue = 2 | pages = 458–470 | date = January 2013 | pmid = 22897747 | pmc = 3572571 | doi = 10.1111/j.1476-5381.2012.02145.x | url = | quote = β-Keto-analogue cathinones also exhibited approximately 10-fold lower affinity for the TA1 receptor compared with their respective non-β-keto amphetamines. [...] Activation of TA1 receptors negatively modulates dopaminergic neurotransmission. Importantly, methamphetamine decreased DAT surface expression via a TA1 receptor-mediated mechanism and thereby reduced the presence of its own pharmacological target (Xie and Miller, 2009). MDMA and amphetamine have been shown to produce enhanced DA and 5-HT release and locomotor activity in TA1 receptor knockout mice compared with wild-type mice (Lindemann et al., 2008; Di Cara et al., 2011). Because methamphetamine and MDMA auto-inhibit their neurochemical and functional effects via TA1 receptors, low affinity for these receptors may result in stronger effects on monoamine systems by cathinones compared with the classic amphetamines. }}</ref><ref name="DiCaraMaggioAloisi2011">{{cite journal | vauthors = Di Cara B, Maggio R, Aloisi G, Rivet JM, Lundius EG, Yoshitake T, Svenningsson P, Brocco M, Gobert A, De Groote L, Cistarelli L, Veiga S, De Montrion C, Rodriguez M, Galizzi JP, Lockhart BP, Cogé F, Boutin JA, Vayer P, Verdouw PM, Groenink L, Millan MJ | title = Genetic deletion of trace amine 1 receptors reveals their role in auto-inhibiting the actions of ecstasy (MDMA) | journal = J Neurosci | volume = 31 | issue = 47 | pages = 16928–16940 | date = November 2011 | pmid = 22114263 | pmc = 6623861 | doi = 10.1523/JNEUROSCI.2502-11.2011 | url = }}</ref>

MDA fully substitutes for MDMA in rodent [[drug discrimination]] tests.<ref name="Oeri2021" /> However, its [[prosocial]] effects in rodents are said to not fully resemble those of MDMA.<ref name="Sáez-BrionesHernández2013" /><ref name="Sáez-BrionesCastroMaass2011">Sáez-Briones P, Castro V, Maass M, Mundaca E, Villagra M, Díaz-Véliz G. Modelo animal de interacción social: administración aguda de MDMA (3-4-metilendioximetanfetamina “Extasis”) y algunos de sus análogos en ratas Sprague-Dawley. Rev. Farmacol. Chile. 2011;4: 72.</ref> MDA also substitutes for [[stimulant]]s like [[dextroamphetamine]] and [[cocaine]] in drug discrimination tests.<ref name="Oeri2021" /><ref name="Sáez-BrionesHernández2013" /><ref name="Nichols1986" /> The (''S'')-[[optical isomerism|optical isomer]] of MDA is more potent than the (''R'')-[[optical isomerism|optical isomer]] as a psychostimulant, possessing greater activity at the [[monoamine transporter]]s.<ref name="Oeri2021" /><ref name="Nichols1986" /> MDA and (''R'')-MDA but not (''S'')-MDA fully substitute for [[serotonergic psychedelic]]s including [[DOM (drug)|DOM]], [[LSD]], and [[mescaline]].<ref name="Oeri2021" /><ref name="HalberstadtChathaKlein2020" /><ref name="Sáez-BrionesHernández2013" /> Similarly, MDA and (''R'')-MDA produce the [[head-twitch response]], a behavioral proxy of [[psychedelic drug|psychedelic]] effects, in rodents.<ref name="HalberstadtChathaKlein2020">{{cite journal | vauthors = Halberstadt AL, Chatha M, Klein AK, Wallach J, Brandt SD | title = Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species | journal = Neuropharmacology | volume = 167 | issue = | article-number = 107933 | date = May 2020 | pmid = 31917152 | pmc = 9191653 | doi = 10.1016/j.neuropharm.2019.107933 | url = http://usdbiology.com/cliff/Courses/Advanced%20Seminars%20in%20Neuroendocrinology/Serotonergic%20Psychedelics%2020/Halberstadt%2020%20Neuropharm%20potency%20of%20hallucinogens%20%20head-twitch.pdf}}</ref> However, the head-twitch response they produce is very weak in magnitude compared to other related psychedelics such as the [[DOx]] drugs.<ref name="HalberstadtChathaKlein2020" /> On the other hand, the response is more similar in magnitude to that of [[Ariadne (drug)|Ariadne]].<ref name="HalberstadtChathaKlein2020" />

In terms of the subjective and behavioral effects of MDA, it is thought that [[serotonin]] release is required for its entactogenic effects, [[dopamine]] release is required for its [[euphoriant]] ([[reward system|rewarding]] and [[drug addiction|addictive]]) effects, dopamine and [[norepinephrine]] release are required for its [[psychostimulant]] effects,  and direct agonism of the serotonin 5-HT<sub>2A</sub> receptor is required for its mild psychedelic effects.<ref name="Oeri2021" /> The entactogenic effects of drugs like MDA are thought to dependent on a precise balance of serotonin and dopamine release as well as serotonin receptor agonism.<ref name="LuethiLiechti2020">{{cite journal | vauthors = Luethi D, Liechti ME | title = Designer drugs: mechanism of action and adverse effects | journal = Arch Toxicol | volume = 94 | issue = 4 | pages = 1085–1133 | date = April 2020 | pmid = 32249347 | pmc = 7225206 | doi = 10.1007/s00204-020-02693-7 | bibcode = 2020ArTox..94.1085L | url = }}</ref><ref name="Baggott2023">{{cite conference | vauthors = Baggott M | title = Beyond Ecstasy: Progress in Developing and Understanding a Novel Class of Therapeutic Medicine | conference = PS2023 [Psychedelic Science 2023, June 19–23, 2023, Denver, Colorado] | date = 23 June 2023 | publisher = [[Multidisciplinary Association for Psychedelic Studies]] | location = Denver, CO | url = https://2023.psychedelicscience.org/sessions/beyond-ecstasy-progress-in-developing-and-understanding-a-novel-class-of-therapeutic-medicine/}}</ref><ref name="Baggott2024">{{cite web | title=Better Than Ecstasy: Progress in Developing a Novel Class of Therapeutic with Matthew Baggott, PhD. | website=YouTube | date=6 March 2024 | url=https://www.youtube.com/watch?v=OnhJvKxwfZI&t=1048 | access-date=20 November 2024}}</ref><ref name="RothmanBaumann2002">{{cite journal | vauthors = Rothman RB, Baumann MH | title = Therapeutic and adverse actions of serotonin transporter substrates | journal = Pharmacol Ther | volume = 95 | issue = 1 | pages = 73–88 | date = July 2002 | pmid = 12163129 | doi = 10.1016/s0163-7258(02)00234-6 | url = }}</ref><ref name="BaggottGarrisonCoyle2019" /> The longer duration of MDA compared to MDMA appears to be related to [[pharmacodynamics]] as opposed to [[pharmacokinetics]], for instance the effects of MDA depending relatively more on serotonin 5-HT<sub>2A</sub> receptor agonism than on serotonin release.<ref name="BaggottGarrisonCoyle2019" />

MDA can produce [[monoaminergic neurotoxin|serotonergic neurotoxic]] effects in rodents.<ref name="Oeri2021" /><ref name="Herndon_2014">{{cite journal | vauthors = Herndon JM, Cholanians AB, Lau SS, Monks TJ | title = Glial cell response to 3,4-(+/-)-methylenedioxymethamphetamine and its metabolites | journal = Toxicological Sciences | volume = 138 | issue = 1 | pages = 130–138 | date = March 2014 | pmid = 24299738 | pmc = 3930364 | doi = 10.1093/toxsci/kft275 }}</ref><ref>{{cite journal | vauthors = Kalant H | title = The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs | journal = CMAJ | volume = 165 | issue = 7 | pages = 917–928 | date = October 2001 | pmid = 11599334 | pmc = 81503 }}</ref> This might in part be due to [[drug metabolism|metabolism]] of MDA.<ref name="de_la_Torre_2004">{{cite journal | vauthors = de la Torre R, Farré M, Roset PN, Pizarro N, Abanades S, Segura M, Segura J, Camí J | display-authors = 6 | title = Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition | journal = Therapeutic Drug Monitoring | volume = 26 | issue = 2 | pages = 137–144 | date = April 2004 | pmid = 15228154 | doi = 10.1097/00007691-200404000-00009 }}</ref> In addition, MDA activates a response of the [[neuroglia]], though this subsides after use.<ref name="Herndon_2014" />

<div style="display:inline-grid; margin-right:15px;">
{| class="wikitable" style="font-size:small;"
|+ Activities of MDMA, its enantiomers, and related compounds
|-
! rowspan="2" | Compound !! colspan="3" | [[Monoamine releasing agent|Monoamine release]] ({{Abbrlink|EC<sub>50</sub>|half-maximal effective concentration}}, nM)
|-
! [[Serotonin releasing agent|Serotonin]] !! [[Norepinephrine releasing agent|Norepinephrine]] !! [[Dopamine releasing agent|Dopamine]]
|-
| [[Amphetamine]] || {{Abbr|ND|No data}} || {{Abbr|ND|No data}} || {{Abbr|ND|No data}}
|-
| {{nbsp}}{{nbsp}}[[Dextroamphetamine|(''S'')-Amphetamine]] (''d'') || 698–1,765 || 6.6–7.2 || 5.8–24.8
|-
| {{nbsp}}{{nbsp}}[[Levoamphetamine|(''R'')-Amphetamine]] (''l'') || {{Abbr|ND|No data}} || 9.5 || 27.7
|-
| [[Methamphetamine]] || {{Abbr|ND|No data}} || {{Abbr|ND|No data}} || {{Abbr|ND|No data}}
|-
| {{nbsp}}{{nbsp}}[[Dextromethamphetamine|(''S'')-Methamphetamine]] (''d'') || 736–1,292 || 12.3–13.8 || 8.5–24.5
|-
| {{nbsp}}{{nbsp}}[[Levomethamphetamine|(''R'')-Methamphetamine]] (''l'') || 4,640 || 28.5 || 416
|-
| '''MDA''' || 160 || 108 || 190
|-
| {{nbsp}}{{nbsp}}(''S'')-MDA (''d'') || 100 || 50 || 98
|-
| {{nbsp}}{{nbsp}}(''R'')-MDA (''l'') || 310 || 290 || 900
|-
| [[Methylenedioxymethamphetamine|MDMA]] || 49.6–72 || 54.1–110 || 51.2–278
|-
| {{nbsp}}{{nbsp}}(''S'')-MDMA (''d'') || 74 || 136 || 142
|-
| {{nbsp}}{{nbsp}}(''R'')-MDMA (''l'') || 340 || 560 || 3,700
|-
| [[Methylenedioxyethylamphetamine|MDEA]] || 47 || 2,608 || 622
|-
| [[Methylbenzodioxolylbutanamine|MBDB]] || 540 || 3,300 || >100,000
|-
| [[5,6-Methylenedioxy-2-aminoindane|MDAI]] || 114 || 117 || 1,334
|-
|- class="sortbottom"
| colspan="4" style="width: 1px; background-color:var(--background-color-notice-subtle,#eaecf0); color:inherit; text-align: center;" | '''Notes:''' The smaller the value, the more strongly the compound produces the effect. '''Refs:'''<ref name="RothmanBaumann2006">{{cite journal | vauthors = Rothman RB, Baumann MH | title = Therapeutic potential of monoamine transporter substrates | journal = Current Topics in Medicinal Chemistry | volume = 6 | issue = 17 | pages = 1845–1859 | date = 2006 | pmid = 17017961 | doi = 10.2174/156802606778249766 }}</ref><ref name="SetolaHufeisenGrande-Allen2003" /><ref name="RothmanBaumannDersch2001">{{cite journal | vauthors = Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, Partilla JS | title = Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin | journal = Synapse | volume = 39 | issue = 1 | pages = 32–41 | date = January 2001 | pmid = 11071707 | doi = 10.1002/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3 | s2cid = 15573624 }}</ref><ref name="RothmanPartillaBaumann2012">{{cite journal | vauthors = Rothman RB, Partilla JS, Baumann MH, Lightfoot-Siordia C, Blough BE | title = Studies of the biogenic amine transporters. 14. Identification of low-efficacy "partial" substrates for the biogenic amine transporters | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 341 | issue = 1 | pages = 251–262 | date = April 2012 | pmid = 22271821 | pmc = 3364510 | doi = 10.1124/jpet.111.188946 }}</ref><ref name="MarusichAntonazzoBlough2016">{{cite journal | vauthors = Marusich JA, Antonazzo KR, Blough BE, Brandt SD, Kavanagh PV, Partilla JS, Baumann MH | title = The new psychoactive substances 5-(2-aminopropyl)indole (5-IT) and 6-(2-aminopropyl)indole (6-IT) interact with monoamine transporters in brain tissue | journal = Neuropharmacology | volume = 101 | pages = 68–75 | date = February 2016 | pmid = 26362361 | pmc = 4681602 | doi = 10.1016/j.neuropharm.2015.09.004 }}</ref><ref name="NagaiNonakaKamimura2007">{{cite journal | vauthors = Nagai F, Nonaka R, Satoh Hisashi Kamimura K | title = The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain | journal = European Journal of Pharmacology | volume = 559 | issue = 2–3 | pages = 132–137 | date = March 2007 | pmid = 17223101 | doi = 10.1016/j.ejphar.2006.11.075 }}</ref><ref name="HalberstadtBrandtWalther2019">{{cite journal | vauthors = Halberstadt AL, Brandt SD, Walther D, Baumann MH | title = 2-Aminoindan and its ring-substituted derivatives interact with plasma membrane monoamine transporters and α2-adrenergic receptors | journal = Psychopharmacology (Berl) | volume = 236 | issue = 3 | pages = 989–999 | date = March 2019 | pmid = 30904940 | pmc = 6848746 | doi = 10.1007/s00213-019-05207-1 | url = }}</ref><ref name="Blough2008">{{cite book | vauthors = Blough B | chapter = Dopamine-releasing agents | veditors = Trudell ML, Izenwasser S | title = Dopamine Transporters: Chemistry, Biology and Pharmacology | pages = 305–320 | date = July 2008 | isbn = 978-0-470-11790-3 | oclc = 181862653 | ol = OL18589888W | publisher = Wiley | location = Hoboken [NJ] | doi = | url = https://books.google.com/books?id=QCagLAAACAAJ | chapter-url = https://bitnest.netfirms.com/external/Books/Dopamine-releasing-agents_c11.pdf }}</ref>
|}
</div>
<div style="display:inline-grid">
{| class="wikitable" style="font-size:small;"
|+ {{Nowrap|MDA, MDMA, and enantiomers at [[serotonin]] [[5-HT2 receptor|5-HT<sub>2</sub> receptor]]s}}
|-
! rowspan="2" | [[Chemical compound|Compound]] !! colspan="2" | [[5-HT2A receptor|5-HT<sub>2A</sub>]] !! colspan="2" | [[5-HT2B receptor|5-HT<sub>2B</sub>]] !! colspan="2" | [[5-HT2C receptor|5-HT<sub>2C</sub>]]
|-
! [[Half-maximal effective concentration|EC<sub>50</sub>]] (nM) !! [[Maximal efficacy|E<sub>max</sub>]] !! [[Half-maximal effective concentration|EC<sub>50</sub>]] (nM) !! [[Maximal efficacy|E<sub>max</sub>]] !! [[Half-maximal effective concentration|EC<sub>50</sub>]] (nM) !! [[Maximal efficacy|E<sub>max</sub>]]
|-
| [[Serotonin]] || 53 || 92% || 1.0 || 100% || 22 || 91%
|-
| MDA || 1,700 || 57% || 190 || 80% || {{Abbr|ND|No data}} || {{Abbr|ND|No data}}
|-
| {{nbsp}}{{nbsp}}(''S'')-MDA (''d'') || 18,200 || 89% || 100 || 81% || 7,400 || 73%
|-
| {{nbsp}}{{nbsp}}(''R'')-MDA (''l'') || 5,600 || 95% || 150 || 76% || 7,400 || 76%
|-
| [[MDMA]] || 6,100 || 55% || 2,000–>20,000 || 32% || {{Abbr|ND|No data}} || {{Abbr|ND|No data}}
|-
| {{nbsp}}{{nbsp}}(''S'')-MDMA (''d'') || 10,300 || 9% || 6,000 || 38% || 2,600 || 53%
|-
| {{nbsp}}{{nbsp}}[[(R)-MDMA|(''R'')-MDMA]] (''l'') || 3,100 || 21% || 900 || 27% || 5,400 || 27%
|- class="sortbottom"
| colspan="7" style="width: 1px; background-color:var(--background-color-notice-subtle,#eaecf0); color:inherit; text-align: center;" | '''Notes:''' The smaller the K<sub>act</sub> or EC<sub>50</sub> value, the more strongly the compound produces the effect. '''Refs:'''<ref name="NashRothBrodkin1994">{{cite journal | vauthors = Nash JF, Roth BL, Brodkin JD, Nichols DE, Gudelsky GA | title = Effect of the R(-) and S(+) isomers of MDA and MDMA on phosphatidyl inositol turnover in cultured cells expressing 5-HT2A or 5-HT2C receptors | journal = Neurosci Lett | volume = 177 | issue = 1–2 | pages = 111–115 | date = August 1994 | pmid = 7824160 | doi = 10.1016/0304-3940(94)90057-4 | url = }}</ref><ref name="SetolaHufeisenGrande-Allen2003" /><ref name="KolaczynskaDucretTrachsel2022">{{cite journal | vauthors = Kolaczynska KE, Ducret P, Trachsel D, Hoener MC, Liechti ME, Luethi D | title = Pharmacological characterization of 3,4-methylenedioxyamphetamine (MDA) analogs and two amphetamine-based compounds: N,α-DEPEA and DPIA | journal = Eur Neuropsychopharmacol | volume = 59 | issue = | pages = 9–22 | date = June 2022 | pmid = 35378384 | doi = 10.1016/j.euroneuro.2022.03.006 | url = https://www.researchgate.net/publication/359686098| doi-access = free }}</ref>
|}
</div>

===Pharmacokinetics===
The [[pharmacokinetics]] of MDA have been studied.<ref name="BaggottGarrisonCoyle2019" /><ref name="BaggottLiGalloway2012">{{cite journal | vauthors=Baggott MJ, Li L, Galloway GP, Scheidweiler KB, Barnes AJ, Huestis MA, Mendelson J | title=Poster Session III (PIII 1-110): PIII-110: Pharmacokinetics of Oral 3,4-Methylenedioxyamphetamine in Humans | journal=Clinical Pharmacology & Therapeutics | volume=91 | issue=Suppl 1 | date=2012 | issn=0009-9236 | doi=10.1038/clpt.2011.363 | pages=S96–S135 | quote = Knowledge of MDA and HMA kinetics in humans is limited to data from MDMA administration studies where minimal formation of these compounds likely leads to inaccurate parameter estimation. We administered a single [98 mg/70 kg body weight] oral dose of MDA to participants in a controlled setting to characterize plasma MDA pharmacokinetics for the first time. [...] Cmax and AUC0-∞ for MDA were 229 ± 39 ng/mL (mean ± SD) and 3636 ± 958 for MDA and 92 ± 61 ng/mL and 1544 ± 741 for the metabolite HMA. Total MDA clearance was 30267 ± 8214 mL/min. There was considerable between-subject variation in metabolite exposure: HMA Cmax and AUC varied over 7-fold and 4-fold, respectively, between the highest and lowest individuals. [...] Pharmacokinetics of MDA resemble those of an iso-molar dose of MDMA, suggesting differences in duration of acute effects between MDA and MDMA are not due to kinetic differences. }}</ref> Its [[duration of action]] has been reported to be about 6 to 8{{nbsp}}hours.<ref name="BaggottSiegristGalloway2010">{{cite journal | vauthors = Baggott MJ, Siegrist JD, Galloway GP, Robertson LC, Coyle JR, Mendelson JE | title = Investigating the mechanisms of hallucinogen-induced visions using 3,4-methylenedioxyamphetamine (MDA): a randomized controlled trial in humans | journal = PLOS ONE | volume = 5 | issue = 12 |article-number=e14074 | date = December 2010 | pmid = 21152030 | pmc = 2996283 | doi = 10.1371/journal.pone.0014074 | doi-access = free | bibcode = 2010PLoSO...514074B }}</ref> The duration of MDA is longer than that of MDMA, about 8{{nbsp}}hours for MDA versus 6{{nbsp}}hours for MDMA.<ref name="BaggottGarrisonCoyle2019" /><ref name="BaggottLiGalloway2012" /> The [[elimination half-life]] of MDA is 10.9{{nbsp}}hours.<ref name="BaggottGarrisonCoyle2019" /> Differences in the duration of MDA versus MDMA may be due [[pharmacodynamics]] rather than pharmacokinetics.<ref name="BaggottGarrisonCoyle2019" /><ref name="BaggottLiGalloway2012" />

==Chemistry==
MDA is a [[substituent|substituted]] [[substituted methylenedioxyphenethylamine|methylenedioxylated]] [[substituted phenethylamine|phenethylamine]] and [[substituted amphetamine|amphetamine]] [[chemical derivative|derivative]]. In relation to other phenethylamines and amphetamines, it is the 3,4-methylenedioxy, α-methyl derivative of [[β-phenylethylamine]], the 3,4-methylenedioxy derivative of [[amphetamine]], and the ''N''-[[desmethyl]] derivative of MDMA.

It is a common [[adulterant]] of illicitly produced MDMA.<ref>{{cite web|url=http://www.ecstasydata.org/stats_substance_by_year.php|title=EcstasyData.org: Test Result Statistics: Substances by Year| work = EcstasyData.org |access-date=2017-06-27}}</ref><ref>{{cite web|url=http://idpc.net/profile/Trans-european-drug-information|title=Trans European Drug Information|website=idpc.net|language=en|access-date=2017-06-27|archive-date=4 November 2021|archive-url=https://web.archive.org/web/20211104230649/https://idpc.net/profile/Trans-european-drug-information|url-status=dead}}</ref>

===Synonyms===
In addition to ''3,4-methylenedioxyamphetamine'', MDA is also known by other chemical synonyms such as the following:

* α-Methyl-3,4-methylenedioxy-β-phenylethylamine
* 1-(3,4-Methylenedioxyphenyl)-2-propanamine
* 1-(1,3-Benzodioxol-5-yl)-2-propanamine

===Synthesis===
MDA is typically [[organic synthesis|synthesized]] from [[essential oil]]s such as [[safrole]] or [[piperonal]]. Common approaches from these [[precursor (chemistry)|precursors]] include:

* Reaction of safrole's [[alkene]] [[functional group]] with a [[halogen]] containing [[mineral acid]] followed by [[amine alkylation]].<ref>{{cite journal | vauthors = Muszynski E | title = [Production of some amphetamine derivatives] | journal = Acta Poloniae Pharmaceutica | volume = 18 | pages = 471–478 | date = 1961 | pmid = 14477621 }}</ref><ref name=ShulginIndex>{{cite book| vauthors = Shulgin A, Manning T, Daley P |title=[[The Shulgin Index|The Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds]]|date=2011|publisher=Transform Press|location=Berkeley, CA|isbn=978-0-9630096-3-0|page=165|edition=1}}</ref>

[[File:MDA_analogs_from_safrole.png|class=skin-invert-image|800px|Synthesis of MDA and related analogs from safrole]]

* [[Wacker oxidation]] of safrole to yield [[3,4-methylenedioxyphenylpropan-2-one]] (MDP2P) followed by [[reductive amination]]<ref name="ShulginIndex" /><ref>{{cite journal | vauthors = Noggle FT, DeRuiter J, Long MJ | title = Spectrophotometric and liquid chromatographic identification of 3,4-methylenedioxyphenylisopropylamine and its N-methyl and N-ethyl homologs | journal = Journal of the Association of Official Analytical Chemists | volume = 69 | issue = 4 | pages = 681–686 | date = 1986 | pmid = 2875058 }}</ref> or via [[Organic redox reaction|reduction]] of its [[oxime]].<ref name="Mannich">{{cite journal | vauthors = Mannich C, Jacobsohn W, Mannich HC |title=Über Oxyphenyl-alkylamine und Dioxyphenyl-alkylamine|journal=Berichte der Deutschen Chemischen Gesellschaft|date=1910|volume=41|issue=1|pages=189–197|doi=10.1002/cber.19100430126|url=https://zenodo.org/record/1426387}}</ref>
* [[Henry reaction]] of piperonal with [[nitroethane]] followed by [[Reduction of nitro compounds|nitro compound reduction]].<ref name="ShulginIndex" /><ref>{{cite journal | vauthors = Ho BT, McIsaac WM, An R, Tansey LW, Walker KE, Englert LF, Noel MB | title = Analogs of alpha-methylphenethylamine (amphetamine). I. Synthesis and pharmacological activity of some methoxy and/or methyl analogs | journal = Journal of Medicinal Chemistry | volume = 13 | issue = 1 | pages = 26–30 | date = January 1970 | pmid = 5412110 | doi = 10.1021/jm00295a007 }}</ref><ref>{{cite journal| vauthors = Butterick JR, Unrau AM |title=Reduction of β-nitrostyrene with sodium bis-(2-methoxyethoxy)-aluminium dihydride. A convenient route to substituted phenylisopropylamines |journal=Journal of the Chemical Society, Chemical Communications|date=1974|volume=8|pages=307–308|doi=10.1039/C39740000307|issue=8}}</ref><ref>{{cite journal | vauthors = Toshitaka O, Hiroaka A |title=Synthesis of Phenethylamine Derivatives as Hallucinogen|journal=Japanese Journal of Toxicology and Environmental Health|date=1992|volume=38|issue=6|pages=571–580|doi=10.1248/jhs1956.38.571|url=https://www.jstage.jst.go.jp/article/jhs1956/38/6/38_6_571/_pdf/-char/en |access-date=20 June 2014|doi-access=free}}</ref><ref name="PiHKAL1991" />
*[[Darzens reaction]] on heliotropin was also done by J. Elks, et al.<ref name="ElksHey1943">{{cite journal| vauthors = Elks J, Hey DH |title=7. β-3 : 4-Methylenedioxyphenylisopropylamine|journal=J. Chem. Soc.|year=1943|pages=15–16|issn=0368-1769|doi=10.1039/JR9430000015}}</ref> This gives [[MDP2P]], which was then subjected to a Leuckart reaction.
* The "two dogs" or "dopeboy" [[Clandestine chemistry|clandestine]] method, starting with [[helional]] as a precursor. First, an oxime is created using hydroxylamine. Then, a [[Beckmann rearrangement]] is performed with nickel acetate to form the amide. Then a [[Hofmann rearrangement]] is done to form the freebase amine of MDA. Then it is purified with an [[acid base extraction]].<ref>{{Cite web|url=https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3973132|title=Does the 'Two Dogs' Method of Clandestine Synthesis Use Precursors That are not Legally Regulated on the Australian East Coast? by Victor Chiruta, Robert D Renshaw :: SSRN|date=28 November 2021 |ssrn=3973132 |accessdate=11 February 2024 | vauthors = Victor C, D R }}</ref>

===Detection in body fluids===
MDA may be quantitated in blood, plasma or urine to monitor for use, confirm a diagnosis of poisoning or assist in the forensic investigation of a traffic or other criminal violation or a sudden death. Some drug abuse screening programs rely on hair, saliva, or sweat as specimens. Most commercial amphetamine immunoassay screening tests cross-react significantly with MDA and major metabolites of MDMA, but chromatographic techniques can easily distinguish and separately measure each of these substances. The concentrations of MDA in the blood or urine of a person who has taken only MDMA are, in general, less than 10% those of the parent drug.<ref>Kolbrich EA, Goodwin RS, Gorelick DA, Hayes RJ, Stein EA, Huestis MA. Plasma pharmacokinetics of 3,4-methyl<wbr />enedioxy<wbr />methamphetamine after controlled oral administration to young adults. Ther. Drug Monit. 30: 320–332, 2008.</ref><ref>{{cite journal | vauthors = Barnes AJ, De Martinis BS, Gorelick DA, Goodwin RS, Kolbrich EA, Huestis MA | title = Disposition of MDMA and metabolites in human sweat following controlled MDMA administration | journal = Clinical Chemistry | volume = 55 | issue = 3 | pages = 454–462 | date = March 2009 | pmid = 19168553 | pmc = 2669283 | doi = 10.1373/clinchem.2008.117093 }}</ref><ref>R. Baselt, ''Disposition of Toxic Drugs and Chemicals in Man'', 9th edition, Biomedical Publications, Seal Beach, California, 2011, pp. 1078–1080.</ref>

===Derivatives and analogues===
[[Structural analogue|Analogue]]s of MDA include its [[positional isomer]] [[2,3-methylenedioxyamphetamine]] (2,3-MDA) and others.

MDA constitutes part of the core structure of the [[beta-adrenergic agonist|β-adrenergic receptor agonist]] [[protokylol]].

==History==
MDA was first synthesized by [[Carl Mannich]] and W. Jacobsohn in 1910.<ref name=Mannich /> It was first taken in July 1930 by [[Gordon Alles]] at a total dose of 126{{nbsp}}mg, who experienced [[hallucinogen]]ic effects, [[well-being]] and [[euphoria]], and [[peripheral nervous system|peripheral]] effects.<ref name="Alles1959a">{{cite book | author=[[Gordon A. Alles]] | chapter = Some Relations Between Chemical Structure and Physiological Action of Mescaline and Related Compounds / Structure and Action of Phenethylamines | veditors = Abramson HA | title = Neuropharmacology: Transactions of the Fourth Conference, September 25, 26, and 27, 1957, Princeton, N. J. | location = New York | publisher = Josiah Macy Foundation | date = 1959 | pages = 181–268 | oclc = 9802642 | url = https://books.google.com/books?id=sDQLAQAAMAAJ&q=%22Some+relations+between+chemical+structure+and+physiological+action+of+mescaline+and+related+compounds%22 | chapter-url = https://bitnest.netfirms.com/external/Books/NeuropharmacologyTrans.4.181#page=5 | archive-url = https://web.archive.org/web/20250321230359/https://bitnest.netfirms.com/external/Books/NeuropharmacologyTrans.4.181#page=5 | archive-date = 21 March 2025 }}</ref><ref name="Alles1959b">{{cite book | author = [[Gordon A. Alles]] | chapter = Subjective Reactions to Phenethylamine Hallucinogens | title = A Pharmacologic Approach to the Study of the Mind | date = 1959 | publisher = CC Thomas | location = Springfield | pages = 238–250 (241–246) | isbn = 978-0-398-04254-7 | url = https://books.google.com/books?id=x45rAAAAMAAJ | chapter-url = https://archive.org/details/pharmacologicapp0000univ/page/238/mode/1up}}</ref><ref name="PsychedelicResearch2008" /> However, he did not subsequently describe these effects until 1959.<ref name="BenzenhöferPassie2010">{{cite journal | vauthors = Benzenhöfer U, Passie T | title = Rediscovering MDMA (ecstasy): the role of the American chemist Alexander T. Shulgin | journal = Addiction | volume = 105 | issue = 8 | pages = 1355–61 | date = August 2010 | pmid = 20653618 | doi = 10.1111/j.1360-0443.2010.02948.x | url = }}</ref><ref name="Alles1959a" /><ref name="Alles1959b" /> Alles later licensed the drug to [[Smith, Kline & French]].<ref name="PsychedelicResearch2008">{{cite web | author = [[Matthew J. Baggott]] | title = The First MDA trip and the measurement of 'mystical experience' after MDA, LSD, and Psilocybin | url = http://psychedelicresearch.org/?p=45 | date = 18 July 2008 | publisher = Psychedelic Research | archive-url = https://archive.today/20120713055811/http://psychedelicresearch.org/?p=45 | archive-date = 13 July 2012}}</ref> MDA was first used in [[animal testing|animal tests]] in 1939, and [[human testing|human trials]] began in 1941 in the exploration of possible therapies for [[Parkinson's disease]].<ref name="Shulgin1978" /> However, it was found to be detrimental in people with Parkinson's disease.<ref name="Shulgin1978" /> The drug was described as having [[analeptic]] effects in humans in 1953.<ref name="Shulgin1978" /> From 1949 to 1957, more than five hundred human subjects were given MDA in an investigation of its potential use as an [[antidepressant]] or [[appetite suppressant]] by [[Smith, Kline & French]].<ref name="Shulgin1978" />

The [[United States Army]] also experimented with the drug, code named EA-1298, while working to develop a [[truth drug]] or incapacitating agent. [[Harold Blauer]] died in January 1953 after being intravenously injected, without his knowledge or consent, with 450&nbsp;mg of the drug as part of [[Project MKUltra]].<ref name="DunlapAndrewsOlson2018">{{cite journal | vauthors = Dunlap LE, Andrews AM, Olson DE | title = Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine | journal = ACS Chem Neurosci | volume = 9 | issue = 10 | pages = 2408–2427 | date = October 2018 | pmid = 30001118 | pmc = 6197894 | doi = 10.1021/acschemneuro.8b00155 | url = https://shaunlacob.com/wp-content/uploads/2020/12/DC-MDMA.pdf}}</ref> MDA was patented as an [[ataractic]] by [[Smith, Kline & French]] in 1960, and as an [[anorectic]] under the trade name "Amphedoxamine" in 1961. MDA began to appear on the recreational drug scene around 1963 to 1964. It was then inexpensive and readily available as a [[research chemical]] from several scientific supply houses. Several researchers, including [[Claudio Naranjo]] and Richard Yensen, have explored MDA in the field of [[psychotherapy]].<ref>{{cite journal | vauthors = Naranjo C, Shulgin AT, Sargent T | title = Evaluation of 3,4-methylenedioxyamphetamine (MDA) as an adjunct to psychotherapy | journal = Medicina et Pharmacologia Experimentalis. International Journal of Experimental Medicine | volume = 17 | issue = 4 | pages = 359–364 | year = 1967 | pmid = 5631047 | doi = 10.1159/000137100 }}</ref><ref>{{cite journal | vauthors = Yensen R, Di Leo FB, Rhead JC, Richards WA, Soskin RA, Turek B, Kurland AA | title = MDA-assisted psychotherapy with neurotic outpatients: a pilot study | journal = The Journal of Nervous and Mental Disease | volume = 163 | issue = 4 | pages = 233–245 | date = October 1976 | pmid = 972325 | doi = 10.1097/00005053-197610000-00002 | s2cid = 41155810 }}</ref>

The [[International Nonproprietary Name]] (INN) ''tenamfetamine'' was recommended by the [[World Health Organization]] (WHO) in 1986.<ref name="WHO1986">{{cite web | title=INN Recommended List 26 | website= World Health Organization (WHO) | date=9 June 1986 | url=https://www.who.int/publications/m/item/inn-rl-26 | ref={{sfnref| World Health Organization (WHO) |1900}} | access-date=3 November 2024}}</ref> It was recommended in the same published list in which the INN of [[2,5-dimethoxy-4-bromoamphetamine]] (DOB), brolamfetamine, was recommended.<ref name="WHO1986" /> These events suggest that MDA and DOB were under development as potential [[pharmaceutical drug]]s at the time.<ref name="WHO1986" /> The [[Multidisciplinary Association for Psychedelic Studies]] (MAPS) was also founded in 1986.<ref name="EmersonPontéJerome2014">{{cite journal | vauthors = Emerson A, Ponté L, Jerome L, Doblin R | title = History and future of the Multidisciplinary Association for Psychedelic Studies (MAPS) | journal = J Psychoactive Drugs | volume = 46 | issue = 1 | pages = 27–36 | date = 2014 | pmid = 24830183 | doi = 10.1080/02791072.2014.877321 | url = https://www.researchgate.net/publication/262381557}}</ref>

[[Matthew J. Baggott]] and colleagues conducted some of the first modern [[clinical study|clinical studies]] of MDA in humans and published their findings in the 2010s.<ref name="BaggottGarrisonCoyle2019" /><ref name="BaggottSiegristGalloway2010" /><ref name="BaggottSiegristCoyle2010" />

==Society and culture==
[[File:MDA.jpg|thumb|right|MDA as prepared for recreational use.]]

===Names===
When MDA was under development as a potential pharmaceutical drug, it was given the [[International Nonproprietary Name]] (INN) of ''tenamfetamine''.<ref name="Elks2014">{{cite book | vauthors = Elks J | title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies | publisher=Springer US | year=2014 | isbn=978-1-4757-2085-3 | url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA1157 | access-date=13 November 2024 | page=1157}}</ref>

===Legal status===
====Australia====
MDA is schedule 9 prohibited substance under the [[Standard for the Uniform Scheduling of Medicines and Poisons|Poisons Standards]].<ref name="Poisons Standard">Poisons Standard (October 2015) [https://www.comlaw.gov.au/Details/F2015L01534/Html/Text#_Toc420496379 comlaw.gov.au]</ref> A schedule 9 substance is listed as a "Substances which may be abused or misused, the manufacture, possession, sale or use of which should be prohibited by law except when required for medical or scientific research, or for analytical, teaching or training purposes with approval of Commonwealth and/or State or Territory Health Authorities."<ref name="Poisons Standard" />

====United States====
MDA is a [[Controlled Substances Act#Schedule I controlled substances|Schedule I controlled substance]] in the US.

==Research==
MDA has been studied in [[entactogen-assisted psychotherapy]].<ref name="Oeri2021" /><ref name="Sáez-BrionesHernández2013" />

==See also==
* [[Substituted methylenedioxyphenethylamine]]

==References==
{{Reflist}}

==External links==
* [https://isomerdesign.com/pihkal/explore/100 MDA - Isomer Design]
* [https://psychonautwiki.org/wiki/MDA MDA - PsychonautWiki]
* [http://www.erowid.org/chemicals/mda/mda.shtml MDA - Erowid]
* [http://www.erowid.org/library/books_online/pihkal/pihkal100.shtml MDA - PiHKAL - Erowid]
* [http://pihkal.info/read.php?domain=pk&id=100 MDA - PiHKAL - Isomer Design]

{{Navboxes
| title = Uses
| titlestyle = background:#ccccff
| list1 = 
{{Entactogens}}
{{Psychedelics}}
{{Stimulants}}
}}
{{Navboxes
| title = [[Pharmacodynamics]]
| titlestyle = background:#ccccff
| list1 = 
{{Monoamine releasing agents}}
{{Serotonin receptor modulators}}
{{TAAR modulators}}
{{Monoamine neurotoxins}}
}}
{{Phenethylamines}}
{{Chemical classes of psychoactive drugs}}

{{DEFAULTSORT:Methylenedioxyamphetamine, 3,4-}}
[[Category:Aphrodisiacs]]
[[Category:5-HT2A agonists]]
[[Category:5-HT2B agonists]]
[[Category:5-HT2C agonists]]
[[Category:Entactogens]]
[[Category:Euphoriants]]
[[Category:Human drug metabolites]]
[[Category:Human pathological metabolites]]
[[Category:Methylenedioxyphenethylamines]]
[[Category:Monoaminergic neurotoxins]]
[[Category:Psychedelic-assisted therapy]]
[[Category:Psychedelic phenethylamines]]
[[Category:Recreational drug metabolites]]
[[Category:Serotonin-norepinephrine-dopamine releasing agents]]
[[Category:Serotonin receptor agonists]]
[[Category:Stimulants]]
[[Category:Substituted amphetamines]]
[[Category:TAAR1 agonists]]
[[Category:TAAR1 antagonists]]
[[Category:VMAT inhibitors]]